Fraser A D, Bryan W
Toxicology Laboratory, Victoria General Hospital, Canada.
J Anal Toxicol. 1995 Sep;19(5):281-4. doi: 10.1093/jat/19.5.281.
This study involved the evaluation of the Abbott TDx serum benzodiazepine assay, a fluorescence polarization immunoassay (FPIA), for the detection of lorazepam, adinazolam, and N-desmethyladinazolam in serum. Precision of the assay was determined by using three control serums containing 75, 300, and 700 ng/mL nordiazepam. Between-run precision studies (N = 22) gave mean values of 76, 306, and 690 ng/mL with coefficients of variation of 6.5, 3.3, and 5.7%, respectively. Percent cross-reactivity of serum lorazepam standards (35-500 ng/mL) ranged from 29 to 69%. The cross-reactivity of serum adinazolam ranged from 40 to 47% between 50 and 150 ng/mL and from 38 to 55% for N-desmethyladinazolam between 50 and 250 ng/mL. Serum specimens (48) collected from individuals known to be receiving lorazepam were analyzed. Twenty-two specimens were positive for benzodiazepines. Serum specimens were collected from 0.25 to 24 h after administering a 15-mg oral dose of adinazolam to six volunteers. The FPIA results were compared with combined high-performance liquid chromatographic (HPLC) results for adinazolam and N-desmethyladinazolam. The FPIA method did not detect benzodiazepines at 0.25 h after administration of adinazolam but did detect benzodiazepines from 0.5 to 24 h after administration. The correlation between HPLC (N-desmethyladinazolam) and FPIA results by regression analysis gave the following: y = 0.937x + 4.449, r = 0.98, n = 15. It was concluded that the Abbott FPIA assay for benzodiazepines can detect lorazepam when prescribed in therapeutic doses and when present at greater than 25 ng/mL and can semiquantitatively detect adinazolam or N-desmethyladinazolam or both when present at concentrations greater than 50 ng/mL.
本研究涉及对雅培TDx血清苯二氮䓬检测法（一种荧光偏振免疫分析法，FPIA）进行评估，以检测血清中的劳拉西泮、阿地唑仑和N-去甲基阿地唑仑。通过使用三种分别含有75、300和700 ng/mL去甲西泮的对照血清来确定该检测法的精密度。批间精密度研究（N = 22）得出的平均值分别为76、306和690 ng/mL，变异系数分别为6.5%、3.3%和5.7%。血清劳拉西泮标准品（35 - 500 ng/mL）的交叉反应率范围为29%至69%。血清阿地唑仑在50至150 ng/mL之间的交叉反应率为40%至47%，N-去甲基阿地唑仑在50至250 ng/mL之间的交叉反应率为38%至55%。对已知正在服用劳拉西泮的个体采集的48份血清标本进行了分析。22份标本的苯二氮䓬检测呈阳性。在给6名志愿者口服15 mg阿地唑仑后0.25至24小时采集血清标本。将FPIA结果与阿地唑仑和N-去甲基阿地唑仑的高效液相色谱（HPLC）联合结果进行比较。FPIA法在阿地唑仑给药后0.25小时未检测到苯二氮䓬，但在给药后0.5至24小时检测到了苯二氮䓬。通过回归分析得出HPLC（N-去甲基阿地唑仑）与FPIA结果之间的相关性如下：y = 0.937x + 4.449，r = 0.98，n = 15。得出的结论是，雅培FPIA苯二氮䓬检测法在治疗剂量下开具且浓度大于25 ng/mL时可检测到劳拉西泮，当阿地唑仑或N-去甲基阿地唑仑或两者浓度大于50 ng/mL时可进行半定量检测。
